MindMed terminates Executive President Miri Halperin Wernli without cause, effective Feb 28, 2025

Definium Therapeutics, Inc.

Employment terminated without cause; effective February 28, 2025.
Reason cited: centralizing management team in the United States for strategic alignment.
No replacement announced; CEO Robert Barrow remains.
Updated corporate presentation filed as Exhibit 99.1 on January 13, 2025.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Miri Halperin Wernli

Executive President

DFTX · Definium Therapeutics, Inc.

Effective: 2025-02-28
Filed: January 13, 2025, 6:59 PM ET

On January 10, 2025, Mind Medicine (MindMed) Inc. (the "Company") notified Miri Halperin Wernli, the Company's Executive President, that it was terminating her employment without cause, effective February 28, 2025, as the Company centralizes its management team in the United States to enhance collaboration and alignment with its strategic goals.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Miri Halperin Wernli was terminated as Executive President at Definium Therapeutics, Inc..

Action: terminated
Role: Executive President

Exact text from the filing

On January 10, 2025, Mind Medicine (MindMed) Inc. (the "Company") notified Miri Halperin Wernli, the Company's Executive President, that it was terminating her employment without cause, effective February 28, 2025, as the Company centralizes its management team in the United States to enhance collaboration and alignment with its strategic goals.

View on SEC.gov

Definium Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-002868

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.